About
Technology
Issues
FAQ
Links
Official Page
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.